Parcourir par sujet "pharmacogenetics"
Voici les éléments 1-14 de 14
-
Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-alpha response in rheumatoid arthritis
(2011)Objective. To investigate the possible influence of tumour necrosis factor-alpha (TNF), TNF receptor I (TNFRI) and TNF receptor II (TNFRII) gene polymorphisms on anti-TNF treatment responsiveness, stratified by autoantibody ... -
Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis
(2022)Azathioprine (AZA) and its metabolite, mercaptopurine (6-MP), are widely used immunosuppressant drugs. Polymorphisms in genes implicated in AZA/6-MP metabolism, reportedly, could account in part for their potential toxicity. ... -
Determination of N-acetylation phenotyping in a Greek population using caffeine as a metabolic probe
(1998)Studies of isoniazid, the well known antituberculosis drug, have revealed that N-acetylation polymorphism, is of great clinical importance. In humans, N-acetylation is one of the most important pathways in the inactivation ... -
Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach
(2022)Available drugs have been used as an urgent attempt through clinical trials to minimize severe cases of hospitalizations with Coronavirus disease (COVID-19), however, there are limited data on common pharmacogenomics ... -
Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention
(2018)Adverse drug reactions (ADRs) affect many patients and remain a major public health problem, as they are a common cause of morbidity and mortality. It is estimated that ADRs are responsible for about 6% of hospital admissions ... -
Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept
(2019)Research in rheumatoid arthritis (RA) is increasingly focused on the discovery of biomarkers that could enable personalized treatments. The genetic biomarkers associated with the response to TNF inhibitors (TNFi) are among ... -
FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors
(2017)Psoriasis is a multifactorial skin disease affecting ∼2% of world's population, causing a dramatic decrease in patients' quality of life and a significant increase in health-care expenses. Biological agents such as the ... -
FcγRIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: A meta-analysis of genetic risk
(2016)Purpose: Low-affinity variants FcγRIIIa-V158F and FcγRI-Ia-H131R may alter response to rituximab-based chemotherapy in diffuse large B-cell lymphoma (DLBCL) but available clinical evidence is inconclusive. Our purpose was ... -
Immune-Related Gene Polymorphisms and Pharmacogenetic Studies in Nephrology
(2021)A large subgroup of patients with chronic kidney disease still encounter serious adverse effects and lack of responsiveness to medications, possibly because of the interindividual genetic variability in genes involved in ... -
Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the greek population
(2012)Background: Although biologic therapies have revolutionized the treatment of psoriasis, patients exhibit a substantial heterogeneous response that could be due to complex genetic heterogeneity. Objective: The aim of this ... -
Pharmacogenetics and psoriasis: Is targeted treatment a possibility?
(2017)[No abstract available] -
A systematic review and meta-analysis of pharmacogenetic studies in patients with chronic kidney disease
(2021)Chronic kidney disease (CKD) is an important global public health problem due to its high prevalence and morbidity. Although the treatment of nephrology patients has changed considerably, ineffectiveness and side effects ... -
A systematic review of cost effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives
(2010)Anticoagulant therapy with coumarin derivatives is often sub- or supra-therapeutic, resulting in an increased risk of thromboembolic events or hemorrhage, respectively. Pharmacogenetic-guided dosing has been proposed as ... -
Tumor chemosensitivity assays are helpful for personalized Cytotoxic treatments in cancer patients
(2021)Tumor chemosensitivity assays (TCAs), also known as drug response assays or individualized tumor response tests, have been gaining attention over the past few decades. Although there have been strong positive correlations ...